AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04166968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A-tDCS)
Description: Anodal tDCS will be performed for 20 minutes over the affected hemisphere with an intensity set to 2 mA
Study NCT04166968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (C-tDCS)
Description: Cathodal tDCS will be performed for 20 minutes over the unaffected hemisphere with an intensity set to 2 mA
Study NCT04166968 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation (sham-tDCS)
Description: placebo stimulation
Study NCT04166968 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neuromotor training
Description: conventional neuromotor treatment
Study NCT04166968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromotor training
Description: conventional neuromotor treatment
Study NCT03875495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temferon
Description: Genetically modified autologous HSPCs
Study NCT04043611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative physical therapy management
Description: Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I \& II for pain, Grade III \& IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold), Hamstring, Piriformis McKenzie Prone Extension Exercises
Study NCT04043611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELDOA
Description: ELDOA positions (hold for 1 minute,4 alternate days a week) under supervision during session Conservative physical therapy management Tens and hot pack for at least 10 minutes at low back Soft tissue mobilization (Myofascial Release Technique) Maitland's Lumbar segmental mobilization (Grade I \& II for pain, Grade III \& IV for ROM) Traction (Manual general traction) Neurodynamics (Tensioner technique) Home plan after session (Guided low back exercises):Active Stretching (5-10 repetition with 15-20 second hold),Hamstring,Piriformis
Study NCT02194218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine, low dose
Description: 50 mg
Study NCT02194218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine, high dose
Description: 100 mg
Study NCT02536690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
Study NCT02536690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.
Study NCT02536690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.
Study NCT01760681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H- Coil DTMS
Description: 20 daily deep rTMS treatments
Study NCT01760681 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Study NCT03700606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High flow nasal cannula
Description: 8 liters per minute of blended oxygen through Fisher Paykel Optiflow Jr 2 nasal prongs.
Study NCT03700606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal CPAP
Description: Nasal continuous positive airway pressure of 5-7 cm/H20 delivered using Ventilator or bubble cpap device through short nasal prongs or a nasal face mask.
Study NCT02680496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)
Study NCT05118607 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IG1
Description: application of low intensity transcutaneous penile electrical stimulation for 45 minutes using frequency.
Study NCT02323555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paramedic telephone consultation
Study NCT04544033 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: interleuken 6 level measurment
Description: Detection of IL6 level using ELISA technique.
Study NCT04544033 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin-6 Gene-174C detection
Description: The genotyping of the polymorphisms in IL-6 promoter G-174C (rs1800795) will be performed using PCR-RFLP technique.
Study NCT00504634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 1 mg/m\^2 IV On Days 1, 4, 8, and 11.
Study NCT01338090 — intervention group
Intervention type: DRUG
Intervention: 89Zr-bevacizumab
Description: Intravenous injection 120 MBq
Study NCT01338090 — intervention group
Intervention type: DRUG
Intervention: Everolimus
Description: Oral use, 10 mg per day
Study NCT01435928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
Study NCT01435928 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching placebo once daily in the evening with a meal or 30 minutes after eating
Study NCT02680496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: A single walking trial in which the patient walks on a treadmill for 30 minutes at comfortable walking speed (body-weight supported if necessary)
Study NCT02680496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overground
Description: A single walking trial in which the patient walks overground for 30 minutes at comfortable walking speed (body-weight supported if necessary)
Study NCT03043040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone follow up
Description: Already described in previous page
Study NCT03043040 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Already described in previous page
Study NCT03043040 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Already described in previous page
Study NCT02783482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC5107
Description: GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, a follow-up (3 or 4 weeks)
Study NCT01601743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sitting
Description: Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
Study NCT01601743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Running
Description: Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
Study NCT01601743 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
Study NCT01868867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: On line tutorial followed by text messaging during treatment and iPad for patient education
Study NCT03937271 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Traditional Chinese Medicine pattern
Description: Autoimmune disease (AID) as Sjögren's syndrome (SJS), Systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Ankylosing spondylitis (AS) for comparing with the Dry eye syndrome (DES) subjects will take the Traditional Chinese Medicine pattern.
Study NCT01906190 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal influenza vaccine
Description: subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine
Study NCT03668457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to Patients
Description: Multifaceted intervention consisting of:~1. A collaborative care management intervention, including depression education, medication management and behavioral activation.~2. Use of a medication reminder mobile app.
Study NCT03668457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention to Psychiatrists
Description: Educational intervention consisting of theoretical and practical sessions to to improve communication and negotiation abilities, and to develop skills to promote patient-centered care and shared decision-making.
Study NCT03668457 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Other: Usual care Usual care for depressive disorder received in mental health units
Study NCT03668457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Other: Usual care Usual care for depressive disorder received in mental health units
Study NCT01545843 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep scheduling
Description: 8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
Study NCT01545843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: 20-40 mg fluoxetine daily for 8 weeks
Study NCT01545843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: 20-40 mg fluoxetine daily for 8 weeks
Study NCT02284178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced oropharyngeal suction
Description: Deep oropharyngeal suction with catheter every 4 hours
Study NCT02284178 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual Care
Description: Oral suction with suction swab every 4 hours
Study NCT01741012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: 0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
Study NCT00869843 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: RF Ablation
Study NCT01194908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine, LBH589, Tamoxifen
Description: Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2~Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2~Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2~Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2
Study NCT01986725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standardized care (Intervention I)
Description: During treatment and routine follow-up consultations, patients randomized to standard care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.Usual care includes treatment during hospitalization by the gynecologist and the nurses according to the existing guidelines. At each follow-up visit, the gynecologist will conduct a physical examination. The follow-ups include also treatment of adverse effects of the therapy and rehabilitation.
Study NCT01986725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized care + WOMAN-PRO II program (Intervention II)
Description: This intervention is in addition to standard care. Nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments have the goal to support women's self-management abilities in order to deal with occurring symptoms and related distress. Content of the WOMAN-PRO II program designed for this study is summarized in a handbook for professionals including patient clinical pathways and nurse interventions, supplemented by a patient booklet (paper based and electronic version) with tailored information according to patients' needs. The program includes five consultations with an approximate total duration of two hours.
Study NCT01944722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BD Onclarity™ HPV assay on BD Viper™ LT
Description: The BD HPV specimen will be tested with the BD Onclarity™ HPV assay on the BD Viper™ LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
Study NCT01944722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopy
Description: Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
Study NCT03138044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Treatment
Description: This modality of palliative treatment includes initial surgical operation where arterial vascular supply of the tumor carrying liver lobe of the corresponding hepatic artery as well as the extrahepatic collateral arteries (EHCAs) feeding the large HCC (> 5 cms size) under general anesthesia. Four weeks after the operation the tumor is injeted (intralesionally and intravascularly) with absolute ethanol alcohol injections on regular weekly percutaneous sessions until the tumor become saturated and its vascularity rendered inactive.
Study NCT02230930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apomorphine 0.25% (2.5mg/ml)
Description: Apomorphine 0.5% (5mg/ml) will be diluted to 0.25% (2.5mg/ml) by the addition of the same volume physiological saline (NaCl 0.9%).
Study NCT02230930 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Massage with a spiky ball
Description: Each patient will massage skin reactions with a spiky ball 3 times a day for 2 minutes.
Study NCT02230930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone cream 1%
Description: Hydrocortisone cream 1% (1mg/g) will be administered on each nodule one time a day
Study NCT02230930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous hydrocortisone 10mg
Description: Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
Study NCT04099433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vivomixx
Description: Individuals in the interventional arm will undergo daily oral intake of probiotic supplement
Study NCT04099433 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Individuals in the placebo arm will undergo daily oral intake of placebo supplement
Study NCT00734825 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Omnipaque
Description: oral contrast for CT scan
Study NCT04037488 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inbody 320
Description: Total Skeletal muscle mass (SMM), Skeletal muscle index (SMI), Relative Skeletal muscle mass index (RASM), Fat body mass (FBM), Body mass index (BMI), Body fat percentage, Body water content, Edema Value were calculated by Inbody 320
Study NCT01216254 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: classic v high-frequency electrocoagulation
Description: During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
Study NCT01216254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: classic v high-frequency electrocoagulation
Description: During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
Study NCT02766257 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Anesthesia for ambulatory paediatric surgery
Study NCT00239005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Study NCT00239005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Study NCT01095887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Subjects received eculizumab intravenously at the time of transplant, on the day after transplant, then weekly for four weeks. At four weeks post transplant, anti-blood group antibody levels were determined. Subjects may have potentially received eculizumab every two weeks for one year depending on antibody levels.
Study NCT00292227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine patch applied once daily for a 24-hour period.~Rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;
Study NCT00292227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo patch applied once daily for a 24-hour period. Size and number of patches matching to rotigotine dose schedule (patch application days):~Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;
Study NCT00292227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin infusion
Description: Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
Study NCT00292227 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
Study NCT00292227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo infusion
Description: Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
Study NCT02179775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propranolol
Study NCT02179775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quince's oxymel
Study NCT02179775 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00470158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron and zinc combined
Description: Children >= 12 months received an average of 5mg zinc/day, 6.25 Iron/day, and 25IU folic acid/day. children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
Study NCT00470158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron and zinc on separate days
Description: Children >= 12 months received an average of 5mg zinc/day, alternating daily with 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
Study NCT00470158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron
Description: Children >= 12 months received an average 6.25 Iron/day, and 25IU folic acid/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
Study NCT00470158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Children >= 12 months received an average of 5mg zinc/day. Children\<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
Study NCT00470158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Children received daily placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
Study NCT03256188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active classroom
Description: 30 minutes of moderate-to-vigorous physical activity
Study NCT02477267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL spray
Study NCT02477267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL film